Walleye Capital’s AnaptysBio ANAB Stock Holding History

Walleye Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-2,800	Closed	-$46K	–	895
2019 Q4	$46K	Buy	+2,800	New	+$66.2K	﹤0.01%	1512

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Walleye Capital's ANAB Position: Q2 2026 in Review

Walleye Capital sold out of AnaptysBio (ANAB) in Q2 2026, closing a stake of 18,425 shares — an estimated $1.02M sold.

Walleye Capital first reported a position in ANAB in Q2 2019 and held it in 11 quarters. The position peaked at $5.49M in Q3 2024. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Walleye Capital reported no remaining AnaptysBio position as of Q2 2026 after selling out during the quarter.
Walleye Capital sold 18,425 AnaptysBio shares in Q2 2026, an estimated $1.02M.
Walleye Capital first reported a position in AnaptysBio in Q2 2019 and held it in 11 quarters.
Walleye Capital's AnaptysBio position peaked at $5.49M in Q3 2024.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.